2010
Role of dual PI3/Akt and mTOR inhibition in Waldenström's  Macroglobulinemia  
Oncotarget

Epigenetic modifications as key regulators of Waldenström's   Macroglobulinemia biology
Journal of Hematology & Oncology

microRNA-dependent modulation of histone acetylation in Waldenström Macroglobulinemia 
Blood

Lenalidomide, bortezomib, and dexamethasone  combination therapy  in patients with newly diagnosed  Multiple Myeloma 
Blood

Phase II trial of weekly bortezomib in combination with  rituximab in  untreated patients with Waldenström  Macroglobulinemia 
American Journal of Hematology 

Selective inhibition of chymotrypsin-like activity of the  immunoproteasome  and constitutive proteasome in  Waldenstrom  Macroglobulinemia 
Blood

Phase II trial of weekly bortezomib in combination with rituximab in relapsed  or relapsed/refractory Waldenström  Macroglobulinemia 
Journal of Clinical Oncology

Clinical and translational studies of a phase II trial of the  novel oral  AKT inhibitor  perifosine in relapsed or  relapsed/refractory  Waldenström’s Macroglobulinemia 
Clinical Cancer Research

Dual targeting of the PI3K/Akt/mTOR pathway as an anti-tumor strategy in Waldenström’s Macroglobulinemia 
Blood